当前位置： SCI文献检索 > JOURNAL OF CLINICAL PHARMACOLOGY期刊下所有文献 > Pharmacogenetic Analysis of OATP1B1, UGT1A1, and BCRP Variants in Relation to the Pharmacokinetics of Letermovir in Previously Conducted Clinical Studies.

Pharmacogenetic Analysis of OATP1B1, UGT1A1, and BCRP Variants in Relation to the Pharmacokinetics of Letermovir in Previously Conducted Clinical Studies.

Abstract：

:The cytomegalovirus (CMV) viral terminase inhibitor letermovir is indicated for prevention of CMV infection in CMV-seropositive allogeneic hematopoietic stem cell transplant recipients. In this analysis, functional variants in solute carrier organic anion transporter family member 1B1 (SLCO1B1), uridine diphosphate-glucuronosyltransferase 1A1 (UGT1A1), and breast cancer resistance protein (BCRP) were assessed for effects on letermovir pharmacokinetics (PK) using pooled genetic information from 296 participants in 12 phase 1 studies. Letermovir area under the plasma concentration-time curve (AUC) was increased in carriers of the SLCO1B1 variant rs4149056 C allele relative to noncarriers with a geometric mean ratio (GMR) of 1.18 (95% confidence interval [CI], 1.06-1.30) for carriers of 1 copy and 1.42 (1.10-1.84) for carriers of 2 copies of the risk allele C compared with noncarriers. The SLCO1B1 variant rs4149032 T allele was associated with a decrease in letermovir AUC with GMR (95%CI) of 0.93 (0.85-1.02) and 0.82 (0.73-0.92) for carriers of 1 and 2 copies of the risk allele T, respectively, compared with noncarriers. The UGT1A1*6 variant rs4148323 A allele was present predominantly in Asian participants and was associated with an increase in letermovir AUC compared with noncarriers (GMR, 1.36; 95%CI, 1. 1.07-1.74). SLCO1B1 variant rs2306283, UGT1A1*28 TA promoter repeat, and BCRP variant rs2231142 had no effect on letermovir PK. Together, these data suggest that variants of enzymes and transporters that are involved in the disposition of letermovir in vitro may account for some variability in letermovir PK, but do not affect exposure to a clinically relevant extent.

journal_name

J Clin Pharmacol

journal_title

Journal of clinical pharmacology

authors

Kobie J,Guo Z,Cho CR,Menzel K,McCrea JB,Blanchard R,Shaw PM

doi

10.1002/jcph.1420

subject

Has Abstract

pub_date

2019-09-01 00:00:00

pages

1236-1243

issue

9

eissn

0091-2700

issn

1552-4604

journal_volume

59

pub_type

杂志文章

相关文献

JOURNAL OF CLINICAL PHARMACOLOGY文献大全
  • Intraindividual variability in male hepatic CYP3A4 activity assessed by alfentanil and midazolam clearance.

    abstract：:Clinical investigations using isoform-selective probes to phenotype cytochrome P450 activity and interaction studies using isoform-selective inhibitors to determine P450 involvement in drug metabolism assume minimal interday variability in P450 activity. CYP3A4 is the most abundant human P450 isoform and metabolizes a...

    journal_title：Journal of clinical pharmacology

    pub_type： 临床试验,杂志文章

    doi：10.1177/00912709922008290

    authors： Kharasch ED,Jubert C,Senn T,Bowdle TA,Thummel KE

    更新日期：1999-07-01 00:00:00

  • Effect of CYP2C19 genetic polymorphism on pharmacokinetics and pharmacodynamics of a new proton pump inhibitor, ilaprazole.

    abstract：:It is well known that the CYP2C19 genetic polymorphism influences the pharmacokinetics and pharmacodynamics of proton pump inhibitors (PPIs), but no report has addressed the effects on ilaprazole, a newly developed PPI. To investigate the effects of the CYP2C19 genetic polymorphism on the disposition and pharmacodynam...

    journal_title：Journal of clinical pharmacology

    pub_type： 杂志文章

    doi：10.1177/0091270011408611

    authors： Cho H,Choi MK,Cho DY,Yeo CW,Jeong HE,Shon JH,Lee JY,Shin JS,Cho M,Kim DY,Shin JG

    更新日期：2012-07-01 00:00:00

  • Oral enoximone pharmacokinetics in patients with congestive heart failure.

    abstract：:The pharmacokinetics of enoximone and its sulfoxide metabolite were determined following administration of a single oral dose of 1 or 2 mg/kg in seven patients with congestive heart failure, and in two normal volunteers following a single 75-mg capsule, and were compared to those published previously. Plasma concentra...

    journal_title：Journal of clinical pharmacology

    pub_type： 杂志文章

    doi：10.1002/j.1552-4604.1987.tb03083.x

    authors： Lima JJ,Leier CV,Holtz L,Sterechele J,Shields BJ,MacKichan JJ

    更新日期：1987-09-01 00:00:00

  • Influence of food on the bioavailability of trimoprostil: an overview.

    abstract：:The influence of food on the bioavailability of trimoprostil , a new antiulcer prostaglandin E2 derivative, was investigated in healthy male volunteers in four separate studies. Doses of 0.75, 1.5, and 3.0 mg were administered orally in both the presence and absence of food followed by serial blood sampling through 24...

    journal_title：Journal of clinical pharmacology

    pub_type： 杂志文章

    doi：10.1002/j.1552-4604.1984.tb01830.x

    authors： Wills RJ

    更新日期：1984-04-01 00:00:00

  • Serum metabolite/caffeine ratios as a test for liver function.

    abstract：:The aim of this study was to test the usefulness of the metabolite/caffeine ratio for the evaluation of hepatic dysfunction. Subjects with liver cirrhosis and chronic hepatitis, as well as healthy volunteers, were given the oral dose of 300 mg caffeine. Blood samples were collected after 4, 8, and 12 hours. Concentrat...

    journal_title：Journal of clinical pharmacology

    pub_type： 临床试验,杂志文章

    doi：10.1177/0091270004263468

    authors： Jodynis-Liebert J,Flieger J,Matuszewska A,Juszczyk J

    更新日期：2004-04-01 00:00:00

  • Clinical safety of flurbiprofen.

    abstract：:Data from 58 premarketing studies of the nonsteroidal antiinflammatory drug flurbiprofen were pooled for analyses of adverse drug reactions (ADRs). These studies included 5602 patients treated with flurbiprofen (N = 4123), aspirin (N = 1033), or placebo (N = 446) for varying durations. Diagnoses included rheumatoid ar...

    journal_title：Journal of clinical pharmacology

    pub_type： 临床试验,杂志文章

    doi：10.1002/j.1552-4604.1990.tb03604.x

    authors： Brooks CD,Linet OI,Schellenberg D,Turner LF,Defesche CL,Teoh KW,Johnson JH,Assenzo JR

    更新日期：1990-04-01 00:00:00

  • Nonsteroidal antiinflammatory drug modulation of behavioral responses to intrathecal N-methyl-D-aspartate, but not to substance P and amino-methyl-isoxazole-propionic acid in the rat.

    abstract：:Antinociception by nonsteroidal antiinflammatory drugs, notably diclofenac and S(+)-ibuprofen, has traditionally been attributed to peripheral tissue cyclooxygenase inhibition. This study investigates the potential role of the nitric oxide system for the central antinociceptive effects of diclofenac, S(+)-, and R(-)-i...

    journal_title：Journal of clinical pharmacology

    pub_type： 杂志文章

    doi：

    authors： Björkman R,Hallman KM,Hedner J,Hedner T,Henning M

    更新日期：1996-12-01 00:00:00

  • Suppression of lymphocyte interleukin-2 receptor expression by glucocorticoids, cyclosporine, or both.

    abstract：:Although glucocorticoids and cyclosporine are frequently used to treat patients with various types of glomerulopathy, clinical responses to treatment vary considerably. Considerable interindividual heterogeneity in the suppressive effects of glucocorticoids on lymphocyte proliferation in vitro has been previously repo...

    journal_title：Journal of clinical pharmacology

    pub_type： 杂志文章

    doi：10.1002/j.1552-4604.1996.tb04760.x

    authors： Briggs WA,Gao ZH,Xing JJ,Gimenez LF,Samaniego MD,Scheel PJ,Choi MJ,Burdick JF

    更新日期：1996-10-01 00:00:00

  • Intense management of diabetes mellitus: role of glucose control and antiplatelet agents.

    abstract：:Type 2 diabetes has now reached epidemic proportions across the world and is the cause of substantial morbidity and mortality. Patients with diabetes suffer from their mircovascular complications of retinopathy (blindness), nephropathy (renal failure, dialysis), and neuropathy (neropathic pain, trophic ulcers). Howeve...

    journal_title：Journal of clinical pharmacology

    pub_type： 杂志文章,评审

    doi：10.1177/0091270004263045

    authors： Mudaliar S

    更新日期：2004-04-01 00:00:00

  • The effect of renal insufficiency and hemodialysis on the pharmacokinetics of nalmefene.

    abstract：:The disposition of nalmefene, an opioid antagonist intended for the reversal of opioid-induced respiratory depression, and its primary metabolite nalmefene glucuronide, were characterized in adult volunteers with normal renal function and in patients with end-stage renal disease (ESRD). The effect of hemodialysis on t...

    journal_title：Journal of clinical pharmacology

    pub_type： 杂志文章

    doi：10.1002/j.1552-4604.1996.tb04179.x

    authors： Matzke GR,Frye RF,Alexander AC,Reynolds R,Dixon R,Johnston J,Rault RM

    更新日期：1996-02-01 00:00:00

  • Pharmacokinetics and pharmacodynamics of a novel depot formulation of abarelix, a gonadotropin-releasing hormone (GnRH) antagonist, in healthy men ages 50 to 75.

    abstract：:This study evaluated the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of a novel depot formulation of abarelix, a new gonadotropin-releasing hormone (GnRH) antagonist. This was an open-label, sequential two-phase study in healthy male subjects ages 50 to 75. Subjects received a single intramuscular (IM) do...

    journal_title：Journal of clinical pharmacology

    pub_type： 临床试验,杂志文章

    doi：10.1177/0091270004264920

    authors： Wong SL,Lau DT,Baughman SA,Fotheringham N,Menchaca D,Garnick MB

    更新日期：2004-05-01 00:00:00

  • Delavirdine malabsorption in HIV-infected subjects with spontaneous gastric hypoacidity.

    abstract：:To determine the impact of gastric hypoacidity and acidic beverages on delavirdine mesylate pharmacokinetics in HIV-infected subjects, matched subjects with (n = 11) and without (n = 10) gastric hypoacidity received delavirdine 400 mg tid with either water or an acidic beverage (usually orange juice). The pharmacokine...

    journal_title：Journal of clinical pharmacology

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1177/0091270002239826

    authors： Shelton MJ,Hewitt RG,Adams JM,Cox SR,Chambers JH,Morse GD

    更新日期：2003-02-01 00:00:00

  • Clinical Comparison of Dexketoprofen Trometamol and Dipyrone in Postoperative Dental Pain.

    abstract：:A total of 125 outpatients with moderate to severe pain after surgical removal of one impacted third molar were randomly assigned to receive dexketoprofen trometamol 12.5 or 25 mg or dipyrone 575 mg. For first-dose assessments, patients rated their pain intensity and its relief at regular intervals. From 60 min post d...

    journal_title：Journal of clinical pharmacology

    pub_type： 杂志文章

    doi：10.1002/jcph.1998.38.s1.55

    authors： Bagán JV,López Arranz JS,Valencia E,Santamaría J,Eguidazu I,Horas M,Forns M,Zapata A,Artigas R,Mauleón D

    更新日期：1998-12-01 00:00:00

  • Comparison of the Pharmacokinetic Properties of Naloxone Following the Use of FDA-Approved Intranasal and Intramuscular Devices Versus a Common Improvised Nasal Naloxone Device.

    abstract：:For more than a decade, first responders and the general public have been able to treat suspected opioid overdoses using an improvised nasal naloxone device (INND) constructed from a prefilled syringe containing 2 mg of naloxone (1 mg/mL) attached to a mucosal atomization device. In recent years, the U.S. Food and Dru...

    journal_title：Journal of clinical pharmacology

    pub_type： 杂志文章,随机对照试验

    doi：10.1002/jcph.1401

    authors： Krieter PA,Chiang CN,Gyaw S,McCann DJ

    更新日期：2019-08-01 00:00:00

  • The effect of flecainide acetate, a new antiarrhythmic, on plasma digoxin levels.

    abstract：:The possible effect of oral flecainide acetate on steady-state digoxin levels was assessed in 15 healthy men. Each volunteer received digoxin 0.25 mg daily (8 AM) for 22 consecutive days and flecainide 200 mg bid (8 AM and 8 PM) on days 11 through 15. Plasma digoxin and flecainide levels were measured by radioimmunoas...

    journal_title：Journal of clinical pharmacology

    pub_type： 杂志文章

    doi：10.1002/j.1552-4604.1986.tb02898.x

    authors： Weeks CE,Conard GJ,Kvam DC,Fox JM,Chang SF,Paone RP,Lewis GP

    更新日期：1986-01-01 00:00:00

  • Armodafinil and modafinil in patients with excessive sleepiness associated with shift work disorder: a pharmacokinetic/pharmacodynamic model for predicting and comparing their concentration-effect relationships.

    abstract：:Armodafinil, the longer lasting R-isomer of racemic modafinil, improves wakefulness in patients with excessive sleepiness associated with shift work disorder (SWD). Pharmacokinetic studies suggest that armodafinil achieves higher plasma concentrations than modafinil late in a dose interval following equal oral doses. ...

    journal_title：Journal of clinical pharmacology

    pub_type： 杂志文章,随机对照试验

    doi：10.1177/0091270011417825

    authors： Darwish M,Bond M,Ezzet F

    更新日期：2012-09-01 00:00:00

  • Pharmacokinetics of tipifarnib after oral and intravenous administration in subjects with advanced cancer.

    abstract：:The primary objective of this study was to identify intravenous regimens of tipifarnib that would mimic the systemic exposure obtained after the current twice-daily oral administration of tipifarnib. After determination of an intravenous dose that 6 subjects with advanced cancer could tolerate, another 26 subjects wer...

    journal_title：Journal of clinical pharmacology

    pub_type： 杂志文章,随机对照试验

    doi：10.1177/0091270006291034

    authors： Zhang S,Zannikos P,Awada A,Piccart-Gebhart M,Dirix LY,Fumoleau P,Verhaeghe T,Francois M,De Porre P

    更新日期：2006-10-01 00:00:00

  • Anorectic drugs: drug policy making at the state level.

    abstract：:This study outlines the attempts of four states (Louisiana, Kansas, Wisconsin, and Michigan) to restrict anorectic prescriptions. The actions in these four states exemplify the various mechanisms used in regulating anorectics, ranging from educational efforts to legislative enactments. We examine the evidence used in ...

    journal_title：Journal of clinical pharmacology

    pub_type： 杂志文章,评审

    doi：

    authors： Richard BW,Lasagna L

    更新日期：1988-05-01 00:00:00

  • Pharmacokinetics and antihypertensive effects of low dose clonidine during chronic therapy.

    abstract：:Using a sensitive and specific radioimmunoassay the pharmacokinetic disposition of clonidine was determined in hypertensive patients after a single dose and then after 5, 28 and 56 days of chronic dosing with 75 micrograms bd. Following a single dose of clonidine maximal plasma concentrations of 0.34 +/- 0.06 ng/ml we...

    journal_title：Journal of clinical pharmacology

    pub_type： 杂志文章

    doi：10.1002/j.1552-4604.1989.tb03335.x

    authors： Anavekar SN,Howes LG,Jarrott B,Syrjanen M,Conway EL,Louis WJ

    更新日期：1989-04-01 00:00:00

  • A bioequivalence study of oral controlled-release morphine using naltrexone blockade.

    abstract：:Twenty-three normal volunteers who received morphine sulphate (MS Contin) with naltrexone completed this randomized, analytically blinded, two-way crossover comparison of the bioavailability of one 200-mg oral controlled-release morphine sulfate tablet with two 100-mg MSC tablets. Morphine effects were blocked by thre...

    journal_title：Journal of clinical pharmacology

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1002/j.1552-4604.1995.tb04094.x

    authors： Kaiko RF,Grandy RP,Reder RF,Goldenheim PD,Sackler RS

    更新日期：1995-05-01 00:00:00

  • Lack of electrocardiographic effect of dexlansoprazole MR, a novel modified-release formulation of the proton pump inhibitor dexlansoprazole, in healthy participants.

    abstract：:The effect of the proton pump inhibitor dexlansoprazole, an enantiomer of lansoprazole, on QT intervals was assessed after oral administration of a modified-release formulation of dexlansoprazole (dexlansoprazole MR). In this randomized, positive-comparator, placebo-controlled, 4-period crossover study, 40 healthy par...

    journal_title：Journal of clinical pharmacology

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1177/0091270009339188

    authors： Vakily M,Wu J,Atkinson SN

    更新日期：2009-12-01 00:00:00

  • Population pharmacokinetic and pharmacodynamic analyses from a 4-month intradose escalation and its subsequent 12-month dose titration studies for a human monoclonal anti-FGF23 antibody (KRN23) in adults with X-linked hypophosphatemia.

    abstract：:X-linked hypophosphatemia (XLH) is an inherited metabolic bone disease with abnormally elevated serum FGF23 resulting in low renal maximum threshold for phosphate reabsorption, low serum phosphate (Pi) and 1,25-dihydroxyvitamin D levels with subsequent development of short stature and skeletal deformities. KRN23 is a ...

    journal_title：Journal of clinical pharmacology

    pub_type： 杂志文章

    doi：10.1002/jcph.611

    authors： Zhang X,Peyret T,Gosselin NH,Marier JF,Imel EA,Carpenter TO

    更新日期：2016-04-01 00:00:00

  • The impact of suppressing the renin-angiotensin system on atrial fibrillation.

    abstract：:Atrial fibrillation is very common in the United States. After a search of Medline, EMBASE, and CINAHL, 4 trials evaluating inhibitors of the renin-angiotensin system were identified for prevention of new-onset atrial fibrillation, facilitation of electrical cardioversion of atrial fibrillation, and prevention of atri...

    journal_title：Journal of clinical pharmacology

    pub_type： 杂志文章,meta分析

    doi：10.1177/0091270005283284

    authors： Kalus JS,Coleman CI,White CM

    更新日期：2006-01-01 00:00:00

  • Double-blind, single-dose comparison of bromfenac sodium, tramadol, and placebo after oral surgery.

    abstract：:This double-blind, parallel-group study was performed at a single site in patients with moderate or severe pain after oral surgery to remove one or more impacted third molars. Patients recorded their pain intensity at baseline and were then assigned to receive a single dose of bromfenac sodium (25 mg or 50 mg), tramad...

    journal_title：Journal of clinical pharmacology

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1002/j.1552-4604.1998.tb04453.x

    authors： Mehlisch DR

    更新日期：1998-05-01 00:00:00

  • Estimation of the elimination half-life of a drug at any serum concentration when the Km and Vmax of the drug are known: calculations and validation with phenytoin.

    abstract：:A method of estimating the elimination half-life of a drug at any selected serum concentration when the Km and Vmax of that drug are known is described. The method was validated in six patients by determining their Km and Vmax values for phenytoin, using data obtained at two serum concentrations and then using the Km ...

    journal_title：Journal of clinical pharmacology

    pub_type： 杂志文章

    doi：10.1002/j.1552-4604.1987.tb03022.x

    authors： Browne TR,Greenblatt DJ,Evans JE,Szabo GK,Evans BA,Schumacher GE

    更新日期：1987-04-01 00:00:00

  • Population Pharmacokinetics of Adjunctive Lacosamide in Pediatric Patients With Epilepsy.

    abstract：:A pediatric population pharmacokinetic model including covariate effects was developed using data from 2 clinical trials in pediatric patients with epilepsy (SP0847 and SP1047). Lacosamide plasma concentration-time data (n = 402) were available from 79 children with body weights ranging from 6 to 76 kg, and a balanced...

    journal_title：Journal of clinical pharmacology

    pub_type： 杂志文章

    doi：10.1002/jcph.1340

    authors： Winkler J,Schoemaker R,Stockis A

    更新日期：2019-04-01 00:00:00

  • Tolerance of healthy adult males in intravenous infusion of cetiedil, a vasoerythroactive drug.

    abstract：:The intravenous infusion of cetiedil to a group of ten male volunteers elicited atropine-like side effects on salivation, bronchomotor tone and visual accommodation. With repeated infusions of cetiedil, the incidence as well as the duration of the side effects were reduced significantly, indicating the development of ...

    journal_title：Journal of clinical pharmacology

    pub_type： 杂志文章

    doi：10.1002/j.1552-4604.1982.tb02668.x

    authors： Lewis GP,Cho YW

    更新日期：1982-05-01 00:00:00

  • Trial treatment length optimization with an emphasis on disease progression studies.

    abstract：:Optimal design has been used in the past mainly to optimize sampling schedules for clinical trials. Optimization on design variables other than sampling times has been published in the literature only once before. This study shows, as an example, optimization on the length of treatment periods to obtain reliable estim...

    journal_title：Journal of clinical pharmacology

    pub_type： 杂志文章

    doi：10.1177/0091270008329560

    authors： Hennig S,Nyberg J,Hooker AC,Karlsson MO

    更新日期：2009-03-01 00:00:00

  • Pharmacokinetics and pharmacodynamics of figitumumab, a monoclonal antibody targeting the insulin-like growth factor 1 receptor, in healthy participants.

    abstract：:This study determined the pharmacokinetics (PK) of figitumumab and its effects on insulin-like growth factor (IGF) axis-related biomarkers, following a single intravenous dose (10 [n = 16] and 20 [n = 12] mg/kg) in healthy adults. Serial blood sampling for PK and biomarkers was conducted up to 84 days postdose. A dose...

    journal_title：Journal of clinical pharmacology

    pub_type： 杂志文章

    doi：10.1177/0091270011432934

    authors： Yin D,Sleight B,Alvey C,Hansson AG,Bello A

    更新日期：2013-01-01 00:00:00

  • Model-based analysis of covariate effects on population pharmacokinetics of thrombomodulin alfa in patients with disseminated intravascular coagulation and normal subjects.

    abstract：:Thrombomodulin alfa is the recombinant extracellular domain of human thrombomodulin, which shows anticoagulation activity. To elucidate the pharmacokinetics of thrombomodulin alfa in patients with disseminated intravascular coagulation (DIC), population pharmacokinetic (PPK) analysis was performed using plasma concent...

    journal_title：Journal of clinical pharmacology

    pub_type： 杂志文章,多中心研究

    doi：10.1177/0091270010381900

    authors： Tsuruta K,Yamada Y,Serada M,Tanigawara Y

    更新日期：2011-09-01 00:00:00